The Company obtained approval in the U.S. in June  2013 for MyCAMINE (generic name: micafungin sodium), a  candin-type antifungal agent, for additional indication. The  indication is for injection by intravenous infusion for the  treatment of pediatric patients four months and older with  candidemia, acute disseminated candidiasis, candida peri- tonitis and abscesses, esophageal candidiasis, and the  prophylaxis of candida infections in patients undergoing  hematopoietic stem cell transplantation. The Company obtained approval in the U.S. in July  2013 for extended release capsules of tacrolimus hydrate  (generic name), an immunosuppressant, for the indication  of prophylaxis of organ rejection in patients receiving a  kidney transplant. The product was launched the following  month under the brand name ASTAGRAF XL. For XTANDI (generic name: enzalutamide, develop- ment code: MDV3100) additional indication applications  were submitted in the U.S. in March 2014 and in Europe  the following month for the treatment of men with meta- static castration-resistant prostate cancer who have not  received chemotherapy. (Clinical Development in Japan) The Company obtained approval in June 2013 for Prograf  (generic name: tacrolimus hydrate), an immunosuppres- sant, for the additional indication of interstitial pneumonia  associated with polymyositis/dermatomyositis. With respect to the orally disintegrating tablet that is  being developed as an additional formulation of Irribow  (generic name: ramosetron hydrochloride) for the indication  of diarrhea-predominant irritable bowel syndrome in males,  the Company obtained approval in August 2013. The  product was launched under the brand name Irribow OD  Tablets in January 2014. With respect to the hypnosedative Dormicum (generic  name: midazolam), the Company obtained approval for an  additional indication for use in sedation during surgery and  procedures for dental, oral and maxillofacial care in Decem- ber 2013. In January 2014, the Company obtained approval for  the selective SGLT2 inhibitor Suglat (generic name:  Ipragliflozin L-Proline, development code: ASP1941) for the  treatment of type 2 diabetes, and launched it in April of the  same year. Astellas Pharma Inc.  _ Annual Report 2014 96 In May 2013, the Company entered into an agreement  for a strategic alliance in Japan with Amgen Inc. of the U.S.  The alliance consists of two elements. The first element is a  long-term collaboration between the two companies that  will focus on the co-development and co-commercializa- tion in Japan of five Amgen pipeline medicines, which are  mainly biological products. The five medicines are a hyper- lipidemia agent (development code: AMG 145), an osteo- porosis agent (development code: AMG 785) and three  treatments for cancer (development code: AMG 102, AMG  337 and AMG 103). The second element is the establish- ment of a joint venture company (Amgen Astellas Bio- Pharma KK), through which the two companies will work  together. Having started operations in October 2013,  Amgen Astellas BioPharma KK will work with the Company  on the co-development and co-commercialization in Japan  of the above-mentioned five pipeline medicines. The Company is proactively promoting utilization of the  “Multi-Track” process. This approach includes having mul- tiple strategies at every stage of the R&D process and  promoting the uptake of innovative research, as well as  constructing a high-quality and robust pipeline for the  Company while at the same time managing risks and costs  through the effective use of outside resources. As part of  this approach, in April 2013 the Company entered into an  exclusive license agreement with Tacurion Pharma, Inc., a  company operated by Drais Pharmaceuticals, Inc. of the  U.S., regarding ASP7035, which is currently developed for  the treatment of nocturia. In April 2013, the Company entered into a collaboration  agreement with Ambrx Inc. of the U.S. regarding technol- ogy for next-generation antibody drug conjugates (“ADCs”)  in the field of oncology. Under the agreement, the Com- pany received worldwide rights to develop and commer- cialize ADCs for oncology. Initiatives to Optimize the Allocation of Resources in R&D For XTANDI, the Company obtained approval for the  indication of castration-resistant prostate cancer in March  2014, and launched it in May of the same year.